{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:28:49Z","timestamp":1794266929700,"version":"4.9.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,6,17]],"date-time":"2010-06-17T00:00:00Z","timestamp":1276732800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The proto-oncogene Src is an important non-receptor protein tyrosine kinase involved in signaling pathways that control cell adhesion, growth, migration and differentiation. It negatively regulates osteoblast activity, and, as such, its inhibition is a potential means to prevent bone loss. Dasatinib is a new dual Src\/Bcr-Abl tyrosine kinase inhibitor initially developed for the treatment of chronic myeloid leukemia. It has also shown promising results in preclinical studies in various solid tumors. However, its effects on the differentiation of human osteoblasts have never been examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated the effects of dasatinib on bone marrow-derived mesenchymal stromal cells (MSC) differentiation into osteoblasts, in the presence or absence of a mixture of dexamethasone, ascorbic acid and \u03b2-glycerophosphate (DAG) for up to 21 days. The differentiation kinetics was assessed by evaluating mineralization of the extracellular matrix, alkaline phosphatase (ALP) activity, and expression of osteoblastic markers (receptor activator of nuclear factor kappa B ligand [RANKL], bone sialoprotein [BSP], osteopontin [OPN]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Dasatinib significantly increased the activity of ALP and the level of calcium deposition in MSC cultured with DAG after, respectively, 7 and 14 days; it upregulated the expression of BSP and OPN genes independently of DAG; and it markedly downregulated the expression of RANKL gene and protein (decrease in RANKL\/OPG ratio), the key factor that stimulates osteoclast differentiation and activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results suggest a dual role for dasatinib in both (i) stimulating osteoblast differentiation leading to a direct increase in bone formation, and (ii) downregulating RANKL synthesis by osteoblasts leading to an indirect inhibition of osteoclastogenesis. Thus, dasatinib is a potentially interesting candidate drug for the treatment of osteolysis through its dual effect on bone metabolism.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/1471-2407-10-298","type":"journal-article","created":{"date-parts":[[2010,6,17]],"date-time":"2010-06-17T14:15:35Z","timestamp":1276784135000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts"],"prefix":"10.1186","volume":"10","author":[{"given":"Hichame","family":"Id Boufker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Lagneaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Najar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Piccart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghanem","family":"Ghanem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Body","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Journ\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,6,17]]},"reference":[{"key":"2097_CR1","doi-asserted-by":"publisher","first-page":"75S","DOI":"10.1016\/S8756-3282(02)00715-9","volume":"30","author":"JJ Body","year":"2002","unstructured":"Body JJ: Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis. Bone. 2002, 30: 75S-79S. 10.1016\/S8756-3282(02)00715-9.","journal-title":"Bone"},{"key":"2097_CR2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1172\/JCI24281","volume":"115","author":"GD Roodman","year":"2005","unstructured":"Roodman GD, Windle JJ: Paget disease of bone. J Clin Invest. 2005, 115: 200-208.","journal-title":"J Clin Invest"},{"key":"2097_CR3","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1017\/S1462399408000616","volume":"10","author":"GA Clines","year":"2008","unstructured":"Clines GA, Guise TA: Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med. 2008, 10: e7-10.1017\/S1462399408000616.","journal-title":"Expert Rev Mol Med"},{"key":"2097_CR4","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1359\/jbmr.2003.18.6.1088","volume":"18","author":"GJ Atkins","year":"2003","unstructured":"Atkins GJ, Kostakis P, Pan B, et al: RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res. 2003, 18: 1088-1098. 10.1359\/jbmr.2003.18.6.1088.","journal-title":"J Bone Miner Res"},{"key":"2097_CR5","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1006\/bbrc.1998.9788","volume":"253","author":"N Nakagawa","year":"1998","unstructured":"Nakagawa N, Kinosaki M, Yamaguchi K, et al: RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun. 1998, 253: 395-400. 10.1006\/bbrc.1998.9788.","journal-title":"Biochem Biophys Res Commun"},{"key":"2097_CR6","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1083\/jcb.96.3.639","volume":"96","author":"B Ecarot-Charrier","year":"1983","unstructured":"Ecarot-Charrier B, Glorieux FH, van der Rest M, Pereira G: Osteoblasts isolated from mouse calvaria initiate matrix mineralization in culture. J Cell Biol. 1983, 96: 639-643. 10.1083\/jcb.96.3.639.","journal-title":"J Cell Biol"},{"key":"2097_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.bcmd.2004.08.019","volume":"33","author":"D Zipori","year":"2004","unstructured":"Zipori D: Mesenchymal stem cells: harnessing cell plasticity to tissue and organ repair. Blood Cells Mol Dis. 2004, 33: 211-215. 10.1016\/j.bcmd.2004.08.019.","journal-title":"Blood Cells Mol Dis"},{"key":"2097_CR8","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/07853890500371957","volume":"37","author":"HK Vaananen","year":"2005","unstructured":"Vaananen HK: Mesenchymal stem cells. Ann Med. 2005, 37: 469-479. 10.1080\/07853890500371957.","journal-title":"Ann Med"},{"key":"2097_CR9","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/jor.1100150410","volume":"15","author":"AK Majors","year":"1997","unstructured":"Majors AK, Boehm CA, Nitto H, Midura RJ, Muschler GF: Characterization of human bone marrow stromal cells with respect to osteoblastic differentiation. J Orthop Res. 1997, 15: 546-557. 10.1002\/jor.1100150410.","journal-title":"J Orthop Res"},{"key":"2097_CR10","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/S8756-3282(02)00970-5","volume":"32","author":"N Schecroun","year":"2003","unstructured":"Schecroun N, Delloye C: Bone-likex nodules formed by human bone marrow stromal cells: comparative study and characterization. Bone. 2003, 32: 252-260. 10.1016\/S8756-3282(02)00970-5.","journal-title":"Bone"},{"key":"2097_CR11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1089\/154732804323099208","volume":"13","author":"J Sammons","year":"2004","unstructured":"Sammons J, Ahmed N, El-Sheemy M, Hassan HT: The role of BMP-6, IL-6, and BMP-4 in mesenchymal stem cell-dependent bone development: effects on osteoblastic differentiation induced by parathyroid hormone and vitamin D(3). Stem Cells Dev. 2004, 13: 273-280. 10.1089\/154732804323099208.","journal-title":"Stem Cells Dev"},{"key":"2097_CR12","doi-asserted-by":"publisher","first-page":"5511","DOI":"10.1210\/en.2003-0273","volume":"144","author":"GK Chan","year":"2003","unstructured":"Chan GK, Miao D, Deckelbaum R, Bolivar I, Karaplis A, Goltzman D: Parathyroid hormone-related peptide interacts with bone morphogenetic protein 2 to increase osteoblastogenesis and decrease adipogenesis in pluripotent C3H10T 1\/2 mesenchymal cells. Endocrinology. 2003, 144: 5511-5520. 10.1210\/en.2003-0273.","journal-title":"Endocrinology"},{"key":"2097_CR13","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.0.CO;2-M","volume":"73","author":"MH Lee","year":"1999","unstructured":"Lee MH, Javed A, Kim HJ, et al: Transient upregulation of CBFA1 in response to bone morphogenetic protein-2 and transforming growth factor beta1 in C2C12 myogenic cells coincides with suppression of the myogenic phenotype but is not sufficient for osteoblast differentiation. J Cell Biochem. 1999, 73: 114-125. 10.1002\/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.0.CO;2-M.","journal-title":"J Cell Biochem"},{"key":"2097_CR14","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.bone.2006.05.003","volume":"39","author":"HV Leskela","year":"2006","unstructured":"Leskela HV, Olkku A, Lehtonen S, et al: Estrogen receptor alpha genotype confers interindividual variability of response to estrogen and testosterone in mesenchymal-stem-cell-derived osteoblasts. Bone. 2006, 39: 1026-1034. 10.1016\/j.bone.2006.05.003.","journal-title":"Bone"},{"key":"2097_CR15","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1359\/jbmr.040115","volume":"19","author":"HT Kha","year":"2004","unstructured":"Kha HT, Basseri B, Shouhed D, et al: Oxysterols regulate differentiation of mesenchymal stem cells: pro-bone and anti-fat. J Bone Miner Res. 2004, 19: 830-840. 10.1359\/JBMR.040115.","journal-title":"J Bone Miner Res"},{"key":"2097_CR16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/(SICI)1097-4644(199702)64:2<295::AID-JCB12>3.0.CO;2-I","volume":"64","author":"N Jaiswal","year":"1997","unstructured":"Jaiswal N, Haynesworth SE, Caplan AI, Bruder SP: Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro. J Cell Biochem. 1997, 64: 295-312. 10.1002\/(SICI)1097-4644(199702)64:2<295::AID-JCB12>3.0.CO;2-I.","journal-title":"J Cell Biochem"},{"key":"2097_CR17","doi-asserted-by":"publisher","first-page":"342","DOI":"10.2174\/187152008783961905","volume":"8","author":"N Rucci","year":"2008","unstructured":"Rucci N, Susa M, Teti A: Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases. Anticancer Agents Med Chem. 2008, 8: 342-349. 10.2174\/187152008783961905.","journal-title":"Anticancer Agents Med Chem"},{"key":"2097_CR18","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1146\/annurev.cellbio.13.1.513","volume":"13","author":"SM Thomas","year":"1997","unstructured":"Thomas SM, Brugge JS: Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol. 1997, 13: 513-609. 10.1146\/annurev.cellbio.13.1.513.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"2097_CR19","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.bbrc.2004.09.171","volume":"324","author":"R Roskoski Jr","year":"2004","unstructured":"Roskoski R: Src protein-tyrosine kinase structure and regulation. Biochem Biophys Res Commun. 2004, 324: 1155-1164. 10.1016\/j.bbrc.2004.09.171.","journal-title":"Biochem Biophys Res Commun"},{"key":"2097_CR20","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.2174\/1381612023393323","volume":"8","author":"CA Metcalf","year":"2002","unstructured":"Metcalf CA, van Schravendijk MR, Dalgarno DC, Sawyer TK: Targeting protein kinases for bone disease: discovery and development of Src inhibitors. Curr Pharm Des. 2002, 8: 2049-2075. 10.2174\/1381612023393323.","journal-title":"Curr Pharm Des"},{"key":"2097_CR21","doi-asserted-by":"publisher","first-page":"6291s","DOI":"10.1158\/1078-0432.CCR-06-0991","volume":"12","author":"BF Boyce","year":"2006","unstructured":"Boyce BF, Xing L, Yao Z, et al: SRC inhibitors in metastatic bone disease. Clin Cancer Res. 2006, 12: 6291s-6295s. 10.1158\/1078-0432.CCR-06-0991.","journal-title":"Clin Cancer Res"},{"key":"2097_CR22","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/sj.emboj.7600073","volume":"23","author":"SK Zaidi","year":"2004","unstructured":"Zaidi SK, Sullivan AJ, Medina R, et al: Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. Embo J. 2004, 23: 790-799. 10.1038\/sj.emboj.7600073.","journal-title":"Embo J"},{"key":"2097_CR23","first-page":"S2","volume-title":"Kidney Int Suppl","author":"BF Boyce","year":"2003","unstructured":"Boyce BF, Xing L, Shakespeare W, et al: Regulation of bone remodeling and emerging breakthrough drugs for osteoporosis and osteolytic bone metastases. Kidney Int Suppl. 2003, S2-5. 10.1046\/j.1523-1755.63.s85.2.x."},{"key":"2097_CR24","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers CL: Chronic myeloid leukemia. N Engl J Med. 1999, 340: 1330-1340. 10.1056\/NEJM199904293401706.","journal-title":"N Engl J Med"},{"key":"2097_CR25","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T O'Hare","year":"2005","unstructured":"O'Hare T, Walters DK, Stoffregen EP, et al: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005, 65: 4500-4505. 10.1158\/0008-5472.CAN-05-0259.","journal-title":"Cancer Res"},{"key":"2097_CR26","doi-asserted-by":"publisher","first-page":"6924","DOI":"10.1158\/1078-0432.CCR-05-0757","volume":"11","author":"FM Johnson","year":"2005","unstructured":"Johnson FM, Saigal B, Talpaz M, Donato NJ: Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res. 2005, 11: 6924-6932. 10.1158\/1078-0432.CCR-05-0757.","journal-title":"Clin Cancer Res"},{"key":"2097_CR27","doi-asserted-by":"publisher","first-page":"9185","DOI":"10.1158\/0008-5472.CAN-05-1731","volume":"65","author":"S Nam","year":"2005","unstructured":"Nam S, Kim D, Cheng JQ, et al: Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 2005, 65: 9185-9189. 10.1158\/0008-5472.CAN-05-1731.","journal-title":"Cancer Res"},{"key":"2097_CR28","doi-asserted-by":"publisher","first-page":"962","DOI":"10.2353\/ajpath.2006.050570","volume":"168","author":"JG Trevino","year":"2006","unstructured":"Trevino JG, Summy JM, Lesslie DP, et al: Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol. 2006, 168: 962-972. 10.2353\/ajpath.2006.050570.","journal-title":"Am J Pathol"},{"key":"2097_CR29","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1038\/onc.2010.73","volume":"29","author":"YC Lee","year":"2010","unstructured":"Lee YC, Huang CF, Murshed M, et al: Src family kinase\/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene. 2010, 29: 3196-207. 10.1038\/onc.2010.73.","journal-title":"Oncogene"},{"key":"2097_CR30","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.gene.2005.12.010","volume":"372","author":"JY Cho","year":"2006","unstructured":"Cho JY, Lee WB, Kim HJ, et al: Bone-related gene profiles in developing calvaria. Gene. 2006, 372: 71-81. 10.1016\/j.gene.2005.12.010.","journal-title":"Gene"},{"key":"2097_CR31","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1139\/o99-005","volume":"76","author":"JE Aubin","year":"1998","unstructured":"Aubin JE: Advances in the osteoblast lineage. Biochem Cell Biol. 1998, 76: 899-910. 10.1139\/bcb-76-6-899.","journal-title":"Biochem Cell Biol"},{"key":"2097_CR32","doi-asserted-by":"publisher","first-page":"6941","DOI":"10.1016\/j.biomaterials.2005.04.059","volume":"26","author":"F von Knoch","year":"2005","unstructured":"von Knoch F, Jaquiery C, Kowalsky M, et al: Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials. 2005, 26: 6941-6949. 10.1016\/j.biomaterials.2005.04.059.","journal-title":"Biomaterials"},{"key":"2097_CR33","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1432-0436.2004.07207003.x","volume":"72","author":"T Tondreau","year":"2004","unstructured":"Tondreau T, Lagneaux L, Dejeneffe M, et al: Bone marrow-derived mesenchymal stem cells already express specific neural proteins before any differentiation. Differentiation. 2004, 72: 319-326. 10.1111\/j.1432-0436.2004.07207003.x.","journal-title":"Differentiation"},{"key":"2097_CR34","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1182\/blood.V98.9.2615","volume":"98","author":"M Reyes","year":"2001","unstructured":"Reyes M, Lund T, Lenvik T, Aguiar D, Koodie L, Verfaillie CM: Purification ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood. 2001, 98: 2615-2625. 10.1182\/blood.V98.9.2615.","journal-title":"Blood"},{"key":"2097_CR35","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1359\/jbmr.2003.18.2.213","volume":"18","author":"C Shui","year":"2003","unstructured":"Shui C, Spelsberg TC, Riggs BL, Khosla S: Changes in Runx2\/Cbfa1 expression and activity during osteoblastic differentiation of human bone marrow stromal cells. J Bone Miner Res. 2003, 18: 213-221. 10.1359\/jbmr.2003.18.2.213.","journal-title":"J Bone Miner Res"},{"key":"2097_CR36","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0142-9612(99)00284-7","volume":"21","author":"MJ Coelho","year":"2000","unstructured":"Coelho MJ, Cabral AT, Fernande MH: Human bone cell cultures in biocompatibility testing. Part I: osteoblastic differentiation of serially passaged human bone marrow cells cultured in alpha-MEM and in DMEM. Biomaterials. 2000, 21: 1087-1094. 10.1016\/S0142-9612(99)00284-7.","journal-title":"Biomaterials"},{"key":"2097_CR37","first-page":"24","volume-title":"J Biomed Biotechnol","author":"RM Salasznyk","year":"2004","unstructured":"Salasznyk RM, Williams WA, Boskey A, Batorsky A, Plopper GE: Adhesion to Vitronectin and Collagen I Promotes Osteogenic Differentiation of Human Mesenchymal Stem Cells. J Biomed Biotechnol. 2004, 24-34. 10.1155\/S1110724304306017."},{"key":"2097_CR38","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1159\/000185506","volume":"22","author":"WF Zambuzzi","year":"2008","unstructured":"Zambuzzi WF, Granjeiro JM, Parikh K, Yuvaraj S, Peppelenbosch MP, Ferreira CV: Modulation of Src activity by low molecular weight protein tyrosine phosphatase during osteoblast differentiation. Cell Physiol Biochem. 2008, 22: 497-506. 10.1159\/000185506.","journal-title":"Cell Physiol Biochem"},{"key":"2097_CR39","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/0092-8674(91)90499-O","volume":"64","author":"P Soriano","year":"1991","unstructured":"Soriano P, Montgomery C, Geske R, Bradley A: Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell. 1991, 64: 693-702. 10.1016\/0092-8674(91)90499-O.","journal-title":"Cell"},{"key":"2097_CR40","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1083\/jcb.151.2.311","volume":"151","author":"M Marzia","year":"2000","unstructured":"Marzia M, Sims NA, Voit S, et al: Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol. 2000, 151: 311-320. 10.1083\/jcb.151.2.311.","journal-title":"J Cell Biol"},{"key":"2097_CR41","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/73542","volume":"24","author":"B Li","year":"2000","unstructured":"Li B, Boast S, de los Santos K, et al: Mice deficient in Abl are osteoporotic and have defects in osteoblast maturation. Nature genetics. 2000, 24: 304-308. 10.1038\/73542.","journal-title":"Nature genetics"},{"key":"2097_CR42","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1124\/mol.105.020172","volume":"69","author":"Z Chen","year":"2006","unstructured":"Chen Z, Lee FY, Bhalla KN, Wu J: Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Molecular pharmacology. 2006, 69: 1527-1533. 10.1124\/mol.105.020172.","journal-title":"Molecular pharmacology"},{"key":"2097_CR43","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1021\/jm049486a","volume":"47","author":"LJ Lombardo","year":"2004","unstructured":"Lombardo LJ, Lee FY, Chen P, et al: Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays. Journal of medicinal chemistry. 2004, 47: 6658-6661. 10.1021\/jm049486a.","journal-title":"Journal of medicinal chemistry"},{"key":"2097_CR44","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1359\/jbmr.070719","volume":"22","author":"S O'Sullivan","year":"2007","unstructured":"O'Sullivan S, Naot D, Callon K, et al: Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res. 2007, 22: 1679-1689. 10.1359\/jbmr.070719.","journal-title":"J Bone Miner Res"},{"key":"2097_CR45","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1365-2184.2007.00438.x","volume":"40","author":"F Fierro","year":"2007","unstructured":"Fierro F, Illmer T, Jing D, et al: Inhibition of platelet-derived growth factor receptorbeta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro. Cell proliferation. 2007, 40: 355-366. 10.1111\/j.1365-2184.2007.00438.x.","journal-title":"Cell proliferation"},{"key":"2097_CR46","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1089\/ten.tea.2009.0230","volume":"16","author":"A Kumar","year":"2010","unstructured":"Kumar A, Salimath BP, Stark GB, Finkenzeller G: Platelet-derived growth factor receptor signaling is not involved in osteogenic differentiation of human mesenchymal stem cells. Tissue engineering. 2010, 16: 983-993. 10.1089\/ten.tea.2009.0230.","journal-title":"Tissue engineering"},{"key":"2097_CR47","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1093\/humrep\/den202","volume":"23","author":"JH Moon","year":"2008","unstructured":"Moon JH, Lee JR, Jee BC, et al: Successful vitrification of human amnion-derived mesenchymal stem cells. Human reproduction (Oxford, England). 2008, 23: 1760-1770. 10.1093\/humrep\/den202.","journal-title":"Human reproduction (Oxford, England)"},{"key":"2097_CR48","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1158\/1541-7786.MCR-08-0219","volume":"7","author":"TJ de Vries","year":"2009","unstructured":"de Vries TJ, Mullender MG, van Duin MA, et al: The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts. Mol Cancer Res. 2009, 7: 476-488. 10.1158\/1541-7786.MCR-08-0219.","journal-title":"Mol Cancer Res"},{"key":"2097_CR49","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/leu.2008.237","volume":"23","author":"N Brownlow","year":"2009","unstructured":"Brownlow N, Mol C, Hayford C, Ghaem-Maghami S, Dibb NJ: Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor. Leukemia. 2009, 23: 590-594. 10.1038\/leu.2008.237.","journal-title":"Leukemia"},{"key":"2097_CR50","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/leu.2008.356","volume":"23","author":"K Vandyke","year":"2009","unstructured":"Vandyke K, Dewar AL, Farrugia AN, et al: Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia. 2009, 23: 994-997. 10.1038\/leu.2008.356.","journal-title":"Leukemia"},{"key":"2097_CR51","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/sj.bjc.6605178","volume":"101","author":"T Koreckij","year":"2009","unstructured":"Koreckij T, Nguyen H, Brown LG, Yu EY, Vessella RL, Corey E: Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. British journal of cancer. 2009, 101: 263-268. 10.1038\/sj.bjc.6605178.","journal-title":"British journal of cancer"},{"key":"2097_CR52","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1464-410X.2008.08249.x","volume":"103","author":"F Saad","year":"2009","unstructured":"Saad F: Src as a therapeutic target in men with prostate cancer and bone metastases. BJU international. 2009, 103: 434-440. 10.1111\/j.1464-410X.2008.08249.x.","journal-title":"BJU international"},{"key":"2097_CR53","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.exphem.2008.12.008","volume":"37","author":"D Tibullo","year":"2009","unstructured":"Tibullo D, Giallongo C, La Cava P, et al: Effects of imatinib mesylate in osteoblastogenesis. Experimental hematology. 2009, 37: 461-468. 10.1016\/j.exphem.2008.12.008.","journal-title":"Experimental hematology"},{"key":"2097_CR54","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1182\/blood-2007-07-104281","volume":"111","author":"S Fitter","year":"2008","unstructured":"Fitter S, Dewar AL, Kostakis P, et al: Long-term imatinib therapy promotes bone formation in CML patients. Blood. 2008, 111: 2538-2547. 10.1182\/blood-2007-07-104281.","journal-title":"Blood"},{"key":"2097_CR55","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.3324\/haematol.12373","volume":"93","author":"S Jonsson","year":"2008","unstructured":"Jonsson S, Olsson B, Ohlsson C, Lorentzon M, Mellstrom D, Wadenvik H: Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia. Haematologica. 2008, 93: 1101-1103. 10.3324\/haematol.12373.","journal-title":"Haematologica"}],"updated-by":[{"DOI":"10.1186\/1471-2407-10-298","type":"expression_of_concern","label":"Expression of concern","source":"publisher","updated":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000}},{"DOI":"10.1186\/s12885-025-13460-1","type":"expression_of_concern","label":"Expression of concern","source":"publisher","updated":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000}}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-10-298.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-10-298\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-10-298","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-10-298.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T11:17:32Z","timestamp":1772709452000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/1471-2407-10-298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,17]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,12]]}},"alternative-id":["2097"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-10-298","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,17]]},"assertion":[{"value":"20 August 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ExpressionOfConcern","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An Editorial Expression of Concern to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12885-025-13460-1","URL":"https:\/\/doi.org\/10.1186\/s12885-025-13460-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"298"}}